Health News


Vitaminworld-091317.jpg Vitamin World, a retailer of vitamins and health supplements, filed for bankruptcy protection and said it has identified 51 stores for closure during the bankruptcy process. The company filed for Chapter 11 reorganization in Delaware Bankruptcy Court on Tuesday. It has listed liabilities of more than $43.6 million and estimated assets in a range of $50 million to $100 million.

CVS-Vending-Machines-091217.jpg CVS Pharmacy will be launching health and wellness vending machines across the country to offer healthy snacks, personal care items as well as over-the-counter products to the customers on the go. The automated machines will be placed in airports, hotels, transportation hubs etc. and can be accessed using credit and debit cards.

Drug maker AstraZeneca (AZN) announced the full results of Phase III FLAURA trial, which support TAGRISSO's clear potential as a new standard of care (SoC) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung...

Fitbit-Dexcom-090717.jpg Wearable fitness device maker Fitbit Inc. has announced a collaboration with glucose-monitoring device company DexCom Inc. that will enable people with diabetes to track their glucose levels on Fitbit's new Ionic smartwatch. Under the collaboration, Fitbit plans to make data from DexCom's continuous glucose monitors or CGM available on Ionic.

Nestle-SweetEarth-090717.jpg Nestlé USA Thursday said it has agreed to buy Sweet Earth, a plant-based foods manufacturer based in Moss Landing, California. With the acquisition, Nestlé forays into the plant-based foods segment, which is growing by double digits and expected to become a $5 billion market by 2020. Launched in...

Elililly-090717.jpg Eli Lilly and Co. (LLY) said Thursday that it plans to cut about 3,500 positions globally, as part of a streamlining plan. It expects to incur charges of about $1.2 billion pre-tax or $0.80 per share after-tax. It expects annualized savings of about $500 million that will begin to be realized in 2018.

Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application or sBLA and granted Priority Review for Gazyva or obinutuzumab in combination with chemotherapy followed by Gazyva alone for people with...

Follow RTT